Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25271505 | 0.98 | BRD4 (0.46) | BRD4POLBOPRM1ATMALDH1A1 | |
| SCHEMBL15760245 | 0.84 | OPRM1 (0.46) | BRD4POLBOPRM1ATMALDH1A1 | |
| SCHEMBL2289941 | 0.81 | — | — | |
| SCHEMBL5215702 | 0.81 | BRD4 (0.41) | BRD4POLBOPRM1ATMALDH1A1 | |
| SCHEMBL567321 | 0.81 | BRD4 (0.41) | BRD4POLBOPRM1ATMALDH1A1 | |
| SCHEMBL567320 | 0.81 | BRD4 (0.41) | BRD4POLBOPRM1ATMALDH1A1 | |
| SCHEMBL28231627 | 0.80 | ALDH1A1 (0.45) | POLBATMALDH1A1LMNAHSD17B10 | |
| SCHEMBL3211657 | 0.80 | POLB (0.47) | BRD4POLBOPRM1ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL30427479 | 0.80 | BRD4 (0.40) | BRD4POLBOPRM1ATMALOX15 | |
| Hydrochloric Acid SCHEMBL7093253 | 0.80 | BRD4 (0.40) | BRD4POLBOPRM1ATMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4431157-A2 | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ONO Pharmaceutical Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-30 | — | — | US | disclosed |
| CN-111757869-B | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3757091-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | ONO Pharmaceutical Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2109364-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | BRD4 788/4885POLB 3180/4885OPRM1 930/4885 |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | BRD4 788/4885POLB 3180/4885OPRM1 930/4885 |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | BRD4 788/4885POLB 3180/4885OPRM1 930/4885 |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | BRD4 788/4885POLB 3180/4885OPRM1 930/4885 |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | BRD4 788/4885POLB 3180/4885OPRM1 930/4885 |
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | BRD4 997/4885POLB 4331/4885OPRM1 1382/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | BRD4 758/4885POLB 3941/4885OPRM1 590/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | BRD4 758/4885POLB 3941/4885OPRM1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.